Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schering-Plough 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Schering-Plough 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

3Q Revenues: $2.8 billion (+9%)

3Q Earnings: $750 million (+142%)

YTD Revenues: $9.0 billion (+13%)

YTD Earnings: $1.9 billion (+97%)

Comments: Revenues do not reflect sales of Vytorin and Zetia, which are accounted as “equity income from a joint venture”. SP’s share of that income was $639 million in 3Q (+27%) and $1.8 billion YTD (+34%). Global pharma sales rose 10% to $2.3 billion in 3Q07, driven by Remicade ($426 million / +34%), Nasonex ($242 million / +10%), and Temodar ($215 million / +20%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters